Sunny founded A2-Ai in January of 2023, a venture dedicated to technology-driven clinical pharmacology and pharmacometrics using modern efficiency tools and automation. Previously, she spent time at Sanofi-Aventis, Amgen, and Pfizer. She co-founded her previous business (Ann Arbor Pharmacometrics Group, “A2PG”) in 2007 after Pfizer's departure from its site in Ann Arbor, Michigan. With A2PG, she worked on hundreds of regulatory submissions for clients throughout its highly successful 15 years of PK/PD consulting, until her company was acquired. As a unique leader who is well-versed in both scientific and business aspects of the drug industry, she frequently helps clients proactively find alternative development pathways.

As CTPO of A2-Ai, Devin works with clients to deliver end-to-end solutions that support quantitative decision-making. Devin specializes in bridging the unique characteristics of each client's IT structure with the needs of the scientific team. Some of his focuses for clients include providing strategies to migrate from existing tools to more modern cloud-based workflows, and building prototype tools and dashboards to solve business challenges. Before joining A2-Ai, Devin worked as a principal solutions engineer to help dozens of organizations ranging from the FDA to small biotech and device manufacturers to develop and implement data science solutions.

Jack Cook joined A2-Ai in June of 2023 as a Senior Vice President of Clinical Pharmacology. Previously he spent 33 years at Pfizer, where he worked in a multitude of therapeutic areas. He is a fellow of the AAPS, has authored/co-authored over 80 peer-reviewed publications, and also served as an industrial representative for the US Food and Drug Administration's Pharmaceutical Science and Clinical Pharmacology Advisory Committees from 2012 to 2019. His current interests include improving therapy by optimizing drug delivery, and the use of modeling and simulation to make rational decisions in drug development.

Linh Nguyen brings over two decades of profound expertise in pharmaceutical research and development. Specializing in both small and large molecules, Linh has a rich history of leading clinical studies across various therapeutic areas, including oncology, neuropathic pain, and inflammation. Her strategic insights in PK/PD modeling and clinical pharmacology have been pivotal in numerous regulatory filings, leading to successful drug approvals in the U.S. and Europe.

Ron Weitzman is a seasoned clinical development executive with over 20 years of experience advancing oncology therapies across solid tumors and hematologic malignancies. He has led the development of small molecules, cytotoxic agents, and monoclonal antibodies, contributing to multiple successful INDs, NDAs, and MAAs. His leadership has guided complex global trials from Phase I through III, including pivotal roles in the development of Avastin, Tasigna, and cabozantinib. Ron’s strategic acumen in regulatory engagement, clinical trial design, and cross-functional team leadership has made him a trusted voice in oncology drug development, supporting sponsors through FDA and EMA interactions and regulatory milestones.

Jaymes Holland brings over 20 years of oncology clinical research and drug development experience in both pharmaceutical and biotech settings. He has contributed to the successful approvals of therapies such as Gleevec, Exjade, Tasigna, Avastin, Cabometyx, and Cometriq. His expertise spans Phases I–III with a focus on label-enabling clinical pharmacology studies, IND strategy, and regulatory execution. Jaymes has been recognized with industry awards at Novartis and Pfizer and is known for his scientific rigor, cross-functional leadership, and ability to navigate complex development challenges with precision and clarity.

Raffaele Baffa is a seasoned oncology drug development leader with over 20 years of experience advancing innovative therapies across global biopharma. He has led clinical and translational strategies for antibody-drug conjugates, CAR-T therapies, and immuno-oncology programs, contributing to multiple INDs and global regulatory approvals, including U.S. BLA and China NDA filings. Raffaele has built and led cross-functional teams spanning Clinical Development, Translational Medicine, Regulatory, and Medical Affairs, and has played a key role in strategic partnerships, BD, and M&A across companies including Pfizer, Sanofi, Servier Pharmaceuticals, and CARsgen Therapeutics.

Rosa brings over 20 years of leadership in clinical pharmacology, DMPK, and bioanalysis across both early- and late-stage drug development. Her strategic oversight has supported multiple regulatory approvals, including Ingrezza, Orilissa, Ongentys, and Crenessity, and she played a pivotal role in advancing Paltusotine toward its anticipated U.S. and EU approvals. Rosa has led cross-functional teams spanning clinical pharmacology, pharmacometrics, and biomarker analysis, and has extensive experience designing and executing complex clinical pharmacology and early development studies in multiple therapeutic areas. Her work has shaped global regulatory submissions and interactions, and she is recognized for her forward-thinking, phase-appropriate strategies that integrate science, compliance, and innovation.